{
  "report_rows": [
    {
      "kpi": "Total Revenue (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$2.90B vs. cons $2.820B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Non-GAAP EPS diluted (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$2.60 vs. cons $2.50",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "da Vinci Procedure Growth (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~15.5% vs. cons 14.5%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY 2026 da Vinci Procedure Growth (FY 2026)",
      "prediction": "BETTER",
      "answer": "guide ~14.5-16% (mid 15.25%) vs. cons 14.85%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY 2026 Non-GAAP Gross Margin (FY 2026)",
      "prediction": "UNCHANGED",
      "answer": "guide 67.5-68.5% maintained vs. cons ~68.0%",
      "confidence": "HIGH"
    },
    {
      "kpi": "ACA/Macro Qualitative Commentary (Q2 2026)",
      "prediction": "BETTER",
      "answer": "guide: no material ACA impact observed in Q2 vs. cautious tone set in Q1",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 7.0,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 9.0,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FOLLOW-THROUGH \u2014 estimate revisions chase out-period math upward as H2 implied quarters move above consensus; short covering adds incremental bid",
  "day5_confidence": "MEDIUM"
}